Publications

1: Gartrell RD, Enzler T, Kim PS, Fullerton BT, Fazlollahi L, Chen AX, Minns HE,

Perni S, Weisberg SP, Rizk EM, Wang S, Oh EJ, Guo XV, Chiuzan C, Manji GA, Bates

SE, Chabot J, Schrope B, Kluger M, Emond J, Rabadán R, Farber D, Remotti HE,

Horowitz DP, Saenger YM. Neoadjuvant chemoradiation alters the immune

microenvironment in pancreatic ductal adenocarcinoma. Oncoimmunology. 2022 May

5;11(1):2066767. doi: 10.1080/2162402X.2022.2066767. PMID: 35558160; PMCID:

PMC9090285.

 

2: Gartrell RD, Blake Z, Rizk EM, Perez-Lorenzo R, Weisberg SP, Simoes I, Esancy

C, Fu Y, Davari DR, Barker L, Finkel G, Mondal M, Minns HE, Wang SW, Fullerton

BT, Lozano F, Chiuzan C, Horst B, Saenger YM. Combination immunotherapy

including OncoVEX^mGMCSF creates a favorable tumor immune micro-

environment in transgenic BRAF murine melanoma. Cancer Immunol Immunother. 2022

Aug;71(8):1837-1849. doi: 10.1007/s00262-021-03088-y. Epub 2022 Jan 9. PMID:

34999916.

 

3: Kang E, Martinez M, Moisander-Joyce H, Saenger YM, Griesemer AD, Kato T,

Yamashiro DJ, Remotti H, Gartrell RD. Stable liver graft post anti-PD1 therapy

as a bridge to transplantation in an adolescent with hepatocellular carcinoma.

Pediatr Transplant. 2022 May;26(3):e14209. doi: 10.1111/petr.14209. Epub 2021

Dec 15. PMID: 34907641; PMCID: PMC9035049.

 

4: Djavid AR, Stonesifer C, Fullerton BT, Wang SW, Tartaro MA, Kwinta BD, Grimes

JM, Geskin LJ, Saenger YM. Etiologies of Melanoma Development and Prevention

Measures: A Review of the Current Evidence. Cancers (Basel). 2021 Sep

30;13(19):4914. doi: 10.3390/cancers13194914. PMID: 34638397; PMCID: PMC8508267.

 

5: Movassaghi M, Chung R, Anderson CB, Stein M, Saenger Y, Faiena I. Overcoming

Immune Resistance in Prostate Cancer: Challenges and Advances. Cancers (Basel).

2021 Sep 23;13(19):4757. doi: 10.3390/cancers13194757. PMID: 34638243; PMCID:

PMC8507531.

 

6: Marks DK, Kucharczyk J, Kim P, Chyong DI, Gartrell RD, Lu Y, Hibshoosh H, Guo

H, Evans TRJ, Lopez J, Kristeleit R, Connolly E, Saenger Y, Kalinsky K.

Quantitative Multiplex Immunofluorescence Evaluation of the Tumor

Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast

Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin. Cancer

Invest. 2021 Jul-Aug;39(6-7):466-472. doi: 10.1080/07357907.2021.1938109. Epub

2021 Jun 21. PMID: 34075851.

 

7: Trager MH, Rizk E, Rose S, Zhu K, Lau B, Fullerton BT, Pradhan J, Moore M,

Srivastava AC, Singer G, Gartrell R, Chang R, Geskin LJ, Saenger YM, Goldenberg

G. Transcriptomic analysis identifies differences in gene expression in actinic

keratoses after treatment with imiquimod and between responders and non

responders. Sci Rep. 2021 Apr 22;11(1):8775. doi: 10.1038/s41598-021-88424-z.

PMID: 33888854; PMCID: PMC8062619.

 

8: Schutt CR, Sun H, Pradhan JS, Saenger Y, Ley J, Adkins D, Ingham M, Ding L,

Van Tine BA. Genomic and neoantigen evolution from primary tumor to first

metastases in head and neck squamous cell carcinoma. Oncotarget. 2021 Mar

16;12(6):534-548. doi: 10.18632/oncotarget.27907. PMID: 33796222; PMCID:

PMC7984826.

 

9: Moore MR, Friesner ID, Rizk EM, Fullerton BT, Mondal M, Trager MH, Mendelson

K, Chikeka I, Kurc T, Gupta R, Rohr BR, Robinson EJ, Acs B, Chang R, Kluger H,

Taback B, Geskin LJ, Horst B, Gardner K, Niedt G, Celebi JT, Gartrell-Corrado

RD, Messina J, Ferringer T, Rimm DL, Saltz J, Wang J, Vanguri R, Saenger YM.

Automated digital TIL analysis (ADTA) adds prognostic value to standard

assessment of depth and ulceration in primary melanoma. Sci Rep. 2021 Feb

2;11(1):2809. doi: 10.1038/s41598-021-82305-1. PMID: 33531581; PMCID:

PMC7854647.

 

10: Moreno-Manuel A, Jantus-Lewintre E, Simões I, Aranda F, Calabuig-Fariñas S,

Carreras E, Zúñiga S, Saenger Y, Rosell R, Camps C, Lozano F, Sirera R. CD5 and

CD6 as immunoregulatory biomarkers in non-small cell lung cancer. Transl Lung

Cancer Res. 2020 Aug;9(4):1074-1083. doi: 10.21037/tlcr-19-445. PMID: 32953486;

PMCID: PMC7481598.

 

11: Marks DK, Gartrell RD, El Asmar M, Boboila S, Hart T, Lu Y, Pan Q, Yu J,

Hibshoosh H, Guo H, Andreopoulou E, Wiechmann L, Crew K, Sparano J, Hershman D,

Connolly E, Saenger Y, Kalinsky K. Akt Inhibition Is Associated With Favorable

Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor

Positive, HER2 Negative Breast Cancer. Front Oncol. 2020 Jun 16;10:968. doi:

10.3389/fonc.2020.00968. PMID: 32612958; PMCID: PMC7308467.

 

12: Trager MH, Coley SM, Dube G, Khan S, Ingham M, Samie FH, Geskin LJ,

McDonnell D, Brouder D, Saenger Y, Carvajal R. Combination checkpoint blockade

for metastatic cutaneous malignancies in kidney transplant recipients. J

Immunother Cancer. 2020 Jun;8(1):e000908. doi: 10.1136/jitc-2020-000908. Erratum

in: J Immunother Cancer. 2021 Jan;9(1): PMID: 32503950; PMCID: PMC7279669.

 

13: Audrey-Bayan C, Trager MH, Gartrell-Corrado RD, Rizk EM, Pradhan J,

Silverman AM, Lopez A, Marks DK, Niedt G, Geskin LJ, Saenger YM. Distinguishing

melanophages from tumor in melanoma patients treated with talimogene

laherparepvec. Melanoma Res. 2020 Aug;30(4):410-415. doi:

10.1097/CMR.0000000000000661. PMID: 32379409.

 

14: Trager MH, Geskin LJ, Saenger YM. Oncolytic Viruses for the Treatment of

Metastatic Melanoma. Curr Treat Options Oncol. 2020 Mar 19;21(4):26. doi:

10.1007/s11864-020-0718-2. PMID: 32266483.

 

15: Seban RD, Moya-Plana A, Antonios L, Yeh R, Marabelle A, Deutsch E, Schwartz

LH, Gómez RGH, Saenger Y, Robert C, Ammari S, Dercle L. Prognostic 18F-FDG PET

biomarkers in metastatic mucosal and cutaneous melanoma treated with immune

checkpoint inhibitors targeting PD-1 and CTLA-4. Eur J Nucl Med Mol Imaging.

2020 Sep;47(10):2301-2312. doi: 10.1007/s00259-020-04757-3. Epub 2020 Mar 23.

PMID: 32206839.

 

16: Yeh R, Trager MH, Rizk EM, Finkel GG, Barker LW, Carvajal RD, Geskin LJ,

Schwartz GK, Schwartz L, Dercle L, Saenger YM. FLT-PET At 6 Weeks Predicts

Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With

Pembrolizumab. Clin Nucl Med. 2020 Apr;45(4):267-275. doi:

10.1097/RLU.0000000000002967. PMID: 32108700; PMCID: PMC8190674.

 

17: Gartrell-Corrado RD, Chen AX, Rizk EM, Marks DK, Bogardus MH, Hart TD,

Silverman AM, Bayan CY, Finkel GG, Barker LW, Komatsubara KM, Carvajal RD, Horst

BA, Chang R, Monod A, Rabadan R, Saenger YM. Linking Transcriptomic and Imaging

Data Defines Features of a Favorable Tumor Immune Microenvironment and

Identifies a Combination Biomarker for Primary Melanoma. Cancer Res. 2020 Mar

1;80(5):1078-1087. doi: 10.1158/0008-5472.CAN-19-2039. Epub 2020 Jan 16. PMID:

31948941; PMCID: PMC7112471.

 

18: Weisberg SP, Carpenter DJ, Chait M, Dogra P, Gartrell-Corrado RD, Chen AX,

Campbell S, Liu W, Saraf P, Snyder ME, Kubota M, Danzl NM, Schrope BA, Rabadan

R, Saenger Y, Chen X, Farber DL. Tissue-Resident Memory T Cells Mediate Immune

Homeostasis in the Human Pancreas through the PD-1/PD-L1 Pathway. Cell Rep. 2019

Dec 17;29(12):3916-3932.e5. doi: 10.1016/j.celrep.2019.11.056. PMID: 31851923;

PMCID: PMC6939378.

 

19: Acs B, Ahmed FS, Gupta S, Wong PF, Gartrell RD, Sarin Pradhan J, Rizk EM,

Gould Rothberg B, Saenger YM, Rimm DL. An open source automated tumor

infiltrating lymphocyte algorithm for prognosis in melanoma. Nat Commun. 2019

Nov 29;10(1):5440. doi: 10.1038/s41467-019-13043-2. PMID: 31784511; PMCID:

PMC6884485.

 

20: Yang J, Lagana SM, Saenger YM, Carvajal RD. Dual checkpoint inhibitor-

associated eosinophilic enteritis. J Immunother Cancer. 2019 Nov 15;7(1):310.

doi: 10.1186/s40425-019-0743-5. PMID: 31730503; PMCID: PMC6858706.

 

21: Kulkarni PM, Robinson EJ, Sarin Pradhan J, Gartrell-Corrado RD, Rohr BR,

Trager MH, Geskin LJ, Kluger HM, Wong PF, Acs B, Rizk EM, Yang C, Mondal M,

Moore MR, Osman I, Phelps R, Horst BA, Chen ZS, Ferringer T, Rimm DL, Wang J,

Saenger YM. Deep Learning Based on Standard H&E Images of Primary Melanoma

Tumors Identifies Patients at Risk for Visceral Recurrence and Death. Clin

Cancer Res. 2020 Mar 1;26(5):1126-1134. doi: 10.1158/1078-0432.CCR-19-1495. Epub

2019 Oct 21. PMID: 31636101; PMCID: PMC8142811.

 

22: Rizk EM, Seffens AM, Trager MH, Moore MR, Geskin LJ, Gartrell-Corrado RD,

Wong W, Saenger YM. Biomarkers Predictive of Survival and Response to Immune

Checkpoint Inhibitors in Melanoma. Am J Clin Dermatol. 2020 Feb;21(1):1-11. doi:

10.1007/s40257-019-00475-1. PMID: 31602560; PMCID: PMC6994371.

 

23: Mokrane FZ, Lu L, Vavasseur A, Otal P, Peron JM, Luk L, Yang H, Ammari S,

Saenger Y, Rousseau H, Zhao B, Schwartz LH, Dercle L. Radiomics machine-learning

signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with

indeterminate liver nodules. Eur Radiol. 2020 Jan;30(1):558-570. doi:

10.1007/s00330-019-06347-w. Epub 2019 Aug 23. PMID: 31444598.

 

24: Newton JM, Hanoteau A, Liu HC, Gaspero A, Parikh F, Gartrell-Corrado RD,

Hart TD, Laoui D, Van Ginderachter JA, Dharmaraj N, Spanos WC, Saenger Y, Young

S, Sikora AG. Immune microenvironment modulation unmasks therapeutic benefit of

radiotherapy and checkpoint inhibition. J Immunother Cancer. 2019 Aug

13;7(1):216. doi: 10.1186/s40425-019-0698-6. PMID: 31409394; PMCID: PMC6693252.

 

25: Seban RD, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S, Moya-Plana A,

Mokrane FZ, Gartrell RD, Finkel G, Barker L, Bigorgne AE, Schwartz LH, Saenger

Y, Robert C, Dercle L. Prognostic and theranostic 18F-FDG PET biomarkers for

anti-PD1 immunotherapy in metastatic melanoma: association with outcome and

transcriptomics. Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2298-2310. doi:

10.1007/s00259-019-04411-7. Epub 2019 Jul 25. PMID: 31346755.

 

26: Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D,

Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT,

Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN,

Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R. Author Correction:

Immune and genomic correlates of response to anti-PD-1 immunotherapy in

glioblastoma. Nat Med. 2019 Jun;25(6):1022. doi: 10.1038/s41591-019-0449-8.

Erratum for: Nat Med. 2019 Mar;25(3):462-469. PMID: 30996326.

 

27: Rizk EM, Gartrell RD, Barker LW, Esancy CL, Finkel GG, Bordbar DD, Saenger

YM. Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer

and Immunotherapy. Hematol Oncol Clin North Am. 2019 Apr;33(2):291-299. doi:

10.1016/j.hoc.2018.12.005. Epub 2019 Jan 17. PMID: 30833001; PMCID: PMC6497069.

 

28: Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D,

Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT,

Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN,

Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R. Immune and genomic

correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019

Mar;25(3):462-469. doi: 10.1038/s41591-019-0349-y. Epub 2019 Feb 11. Erratum in:

Nat Med. 2019 Apr 17;: PMID: 30742119; PMCID: PMC6810613.

 

29: Gartrell RD, Marks DK, Rizk EM, Bogardus M, Gérard CL, Barker LW, Fu Y,

Esancy CL, Li G, Ji J, Rui S, Ernstoff MS, Taback B, Pabla S, Chang R, Lee SJ,

Krolewski JJ, Morrison C, Horst BA, Saenger YM. Validation of Melanoma Immune

Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III

Melanoma. Clin Cancer Res. 2019 Apr 15;25(8):2494-2502. doi:

10.1158/1078-0432.CCR-18-2847. Epub 2019 Jan 15. PMID: 30647081; PMCID:

PMC6594682.

 

30: Hanoteau A, Newton JM, Krupar R, Huang C, Liu HC, Gaspero A, Gartrell RD,

Saenger YM, Hart TD, Santegoets SJ, Laoui D, Spanos C, Parikh F, Jayaraman P,

Zhang B, Van der Burg SH, Van Ginderachter JA, Melief CJM, Sikora AG. Tumor

microenvironment modulation enhances immunologic benefit of chemoradiotherapy. J

Immunother Cancer. 2019 Jan 15;7(1):10. doi: 10.1186/s40425-018-0485-9. Erratum

in: J Immunother Cancer. 2020 Mar;8(1): PMID: 30646957; PMCID: PMC6332704.

 

31: Bayan CY, Lopez AT, Gartrell RD, Komatsubara KM, Bogardus M, Rao N, Chen C,

Hart TD, Enzler T, Rizk EM, Pradhan JS, Marks DK, Geskin LJ, Saenger YM.

Correction to: The Role of Oncolytic Viruses in the Treatment of Melanoma. Curr

Oncol Rep. 2018 Nov 13;20(12):100. doi: 10.1007/s11912-018-0749-z. Erratum for:

Curr Oncol Rep. 2018 Aug 25;20(10):80. PMID: 30426304. (duplicate of next)

 

32: Bayan CY, Lopez AT, Gartrell RD, Komatsubara KM, Bogardus M, Rao N, Chen C,

Hart TD, Enzler T, Rizk EM, Pradhan JS, Marks DK, Geskin LJ, Saenger YM. The

Role of Oncolytic Viruses in the Treatment of Melanoma. Curr Oncol Rep. 2018 Aug

25;20(10):80. doi: 10.1007/s11912-018-0729-3. Erratum in: Curr Oncol Rep. 2018

Nov 13;20(12):100. PMID: 30145781; PMCID: PMC6450085.

 

33: Chen JC, Perez-Lorenzo R, Saenger YM, Drake CG, Christiano AM. IKZF1

Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to

Immunotherapy. Cell Syst. 2018 Jul 25;7(1):92-103.e4. doi:

10.1016/j.cels.2018.05.020. Epub 2018 Jun 27. PMID: 29960886.

 

34: Kyi C, Roudko V, Sabado R, Saenger Y, Loging W, Mandeli J, Thin TH, Lehrer

D, Donovan M, Posner M, Misiukiewicz K, Greenbaum B, Salazar A, Friedlander P,

Bhardwaj N. Therapeutic Immune Modulation against Solid Cancers with

Intratumoral Poly-ICLC: A Pilot Trial. Clin Cancer Res. 2018 Oct

15;24(20):4937-4948. doi: 10.1158/1078-0432.CCR-17-1866. Epub 2018 Jun 27. PMID:

29950349; PMCID: PMC6191332.

 

35: Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D,

Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL,

Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG,

Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus

M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I,

Galluzzi L, Gardner M, Ernstoff MS. Predicting response to checkpoint inhibitors

in melanoma beyond PD-L1 and mutational burden. J Immunother Cancer. 2018 May

9;6(1):32. doi: 10.1186/s40425-018-0344-8. PMID: 29743104; PMCID: PMC5944039.

 

36: Blake Z, Marks DK, Gartrell RD, Hart T, Horton P, Cheng SK, Taback B, Horst

BA, Saenger YM. Complete intracranial response to talimogene laherparepvec

(T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma

brain metastases refractory to dual checkpoint-inhibition. J Immunother Cancer.

2018 Apr 6;6(1):25. doi: 10.1186/s40425-018-0338-6. PMID: 29622046; PMCID:

PMC5887256.

 

37: Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin

KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B,

Rabadan R, Kaufman HL, Drake CG, Horst BA, Saenger YM. Quantitative Analysis of

Immune Infiltrates in Primary Melanoma. Cancer Immunol Res. 2018

Apr;6(4):481-493. doi: 10.1158/2326-6066.CIR-17-0360. Epub 2018 Feb 21. PMID:

29467127; PMCID: PMC5882545.

 

38: Wu CC, Chaudhary KR, Na YH, Welch D, Black PJ, Sonabend AM, Canoll P,

Saenger YM, Wang TJC, Wuu CS, Hei TK, Cheng SK. Quality Assessment of

Stereotactic Radiosurgery of a Melanoma Brain Metastases Model Using a Mouselike

Phantom and the Small Animal Radiation Research Platform. Int J Radiat Oncol

Biol Phys. 2017 Sep 1;99(1):191-201. doi: 10.1016/j.ijrobp.2017.05.016. Epub

2017 May 19. PMID: 28816146; PMCID: PMC5675116.

 

39: Manji GA, Olive KP, Saenger YM, Oberstein P. Current and Emerging Therapies

in Metastatic Pancreatic Cancer. Clin Cancer Res. 2017 Apr 1;23(7):1670-1678.

doi: 10.1158/1078-0432.CCR-16-2319. PMID: 28373365.

 

40: Grigg C, Blake Z, Gartrell R, Sacher A, Taback B, Saenger Y. Talimogene

laherparepvec (T-Vec) for the treatment of melanoma and other cancers. Semin

Oncol. 2016 Dec;43(6):638-646. doi: 10.1053/j.seminoncol.2016.10.005. Epub 2016

Oct 27. PMID: 28061981.

 

41: Blagoev KB, Ting DT, Levine H, Saenger Y, Tlsty TD, Sun B. Introducing

cancer convergence. Cancer Converg. 2017;1(1):3. doi: 10.1186/s41236-017-0003-x.

Epub 2017 Nov 1. PMID: 29623955; PMCID: PMC5876691.

 

42: Beck KM, Dong J, Geskin LJ, Beltrani VP, Phelps RG, Carvajal RD, Schwartz G,

Saenger YM, Gartrell RD. Disease stabilization with pembrolizumab for metastatic

acral melanoma in the setting of autoimmune bullous pemphigoid. J Immunother

Cancer. 2016 Apr 19;4:20. doi: 10.1186/s40425-016-0123-3. PMID: 27096097; PMCID:

PMC4835882.

 

*Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid. (melanoma)

[1] 

43: de Moll EH, Fu Y, Qian Y, Perkins SH, Wieder S, Gnjatic S, Remark R,

Bernardo SG, Moskalenko M, Yao J, Ferringer T, Chang R, Chipuk J, Horst BA,

Birge MB, Phelps RG, Saenger YM. Immune biomarkers are more accurate in

prediction of survival in ulcerated than in non-ulcerated primary melanomas.

Cancer Immunol Immunother. 2015 Sep;64(9):1193-203. doi:

10.1007/s00262-015-1726-0. Epub 2015 Jun 16. PMID: 26076664; PMCID: PMC4581435.

 

Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. (melanoma)

 

44: Saenger Y, de Moll E, Fu Y. Transcriptional profiling of whole blood: a rich

source of immune biomarkers in cancer. Oncoimmunology. 2014 Jul 3;3(7):e944056.

doi: 10.4161/21624011.2014.944056. PMID: 25610728; PMCID: PMC4292516.

 

(unclear)Transcriptional profiling of whole blood: a rich source of immune biomarkers in cancer. (other)

 

45: Moskalenko M, Pan M, Fu Y, de Moll EH, Hashimoto D, Mortha A, Leboeuf M,

Jayaraman P, Bernardo S, Sikora AG, Wolchok J, Bhardwaj N, Merad M, Saenger Y.

Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat

established melanoma with chemo-immunotherapy. Cancer Immunol Res. 2015

Mar;3(3):296-304. doi: 10.1158/2326-6066.CIR-14-0120. Epub 2015 Jan 19. PMID:

25600438; PMCID: PMC4690202.

 

Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy. (melanoma)

 

46: Godefroy E, Gallois A, Idoyaga J, Merad M, Tung N, Monu N, Saenger Y, Fu Y,

Ravindran R, Pulendran B, Jotereau F, Trombetta S, Bhardwaj N. Activation of

toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates

dendritic-cell-mediated inflammatory responses. Cell Rep. 2014 Dec

11;9(5):1856-1870. doi: 10.1016/j.celrep.2014.10.067. Epub 2014 Nov 26. PMID:

25466255; PMCID: PMC4336179.

 

47: Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C,

Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi

FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G,

Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B,

Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola

FM, Thurin M. Future perspectives in melanoma research: meeting report from the

"Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct

28;12:277. doi: 10.1186/s12967-014-0277-z. PMID: 25348889; PMCID: PMC4232645.

 

48: Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K,

Fisher D, Kirkwood J, Oh WK, Friedlander P. Blood mRNA expression profiling

predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014

Jun 15;20(12):3310-8. doi: 10.1158/1078-0432.CCR-13-2906. Epub 2014 Apr 10.

PMID: 24721645.

 

49: Harcharik S, Bernardo S, Moskalenko M, Pan M, Sivendran M, Bell H, Hall LD,

Castillo-Martín M, Fox K, Cordon-Cardo C, Chang R, Sivendran S, Phelps RG,

Saenger Y. Defining the role of CD2 in disease progression and overall survival

among patients with completely resected stage-II to -III cutaneous melanoma. J

Am Acad Dermatol. 2014 Jun;70(6):1036-44. doi: 10.1016/j.jaad.2014.01.914. Epub

2014 Mar 31. PMID: 24698703.

 

50: Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA,

Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong

TD, Jaffee EM. A Listeria vaccine and depletion of T-regulatory cells activate

immunity against early stage pancreatic intraepithelial neoplasms and prolong

survival of mice. Gastroenterology. 2014 Jun;146(7):1784-94.e6. doi:

10.1053/j.gastro.2014.02.055. Epub 2014 Mar 6. PMID: 24607504; PMCID:

PMC4035450.

 

51: Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG,

Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A,

DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK,

Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh

WK, Palucka K, Merad M, Schadt EE, Saenger YM. Dissection of immune gene

networks in primary melanoma tumors critical for antitumor surveillance of

patients with stage II-III resectable disease. J Invest Dermatol. 2014

Aug;134(8):2202-2211. doi: 10.1038/jid.2014.85. Epub 2014 Feb 12. PMID:

24522433; PMCID: PMC4291112.

 

52: Goldufsky J, Sivendran S, Harcharik S, Pan M, Bernardo S, Stern RH,

Friedlander P, Ruby CE, Saenger Y, Kaufman HL. Oncolytic virus therapy for

cancer. Oncolytic Virother. 2013 Sep 23;2:31-46. doi: 10.2147/OV.S38901. PMID:

27512656; PMCID: PMC4918352.

 

53: Bernardo SG, Moskalenko M, Pan M, Shah S, Sidhu HK, Sicular S, Harcharik S,

Chang R, Friedlander P, Saenger YM. Elevated rates of transaminitis during

ipilimumab therapy for metastatic melanoma. Melanoma Res. 2013 Feb;23(1):47-54.

doi: 10.1097/CMR.0b013e32835c7e68. PMID: 23262440.

 

54: Hashimoto D, Chow A, Greter M, Saenger Y, Kwan WH, Leboeuf M, Ginhoux F,

Ochando JC, Kunisaki Y, van Rooijen N, Liu C, Teshima T, Heeger PS, Stanley ER,

Frenette PS, Merad M. Pretransplant CSF-1 therapy expands recipient macrophages

and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp

Med. 2011 May 9;208(5):1069-82. doi: 10.1084/jem.20101709. Epub 2011 May 2.

PMID: 21536742; PMCID: PMC3092347.

 

55: Sivendran S, Glodny B, Pan M, Merad M, Saenger Y. Melanoma immunotherapy. Mt

Sinai J Med. 2010 Nov-Dec;77(6):620-42. doi: 10.1002/msj.20215. PMID: 21105125.

 

56: Sivendran S, Pan M, Kaufman HL, Saenger Y. Herpes simplex virus oncolytic

vaccine therapy in melanoma. Expert Opin Biol Ther. 2010 Jul;10(7):1145-53. doi:

10.1517/14712598.2010.495383. PMID: 20515292.

 

57: Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, Merghoub T,

Houghton AN, Wolchok JD. Improved tumor immunity using anti-tyrosinase related

protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.

Cancer Res. 2008 Dec 1;68(23):9884-91. doi: 10.1158/0008-5472.CAN-08-2233. PMID:

19047169; PMCID: PMC2742375.

 

58: Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the

negative regulation of T-cell activation. Oncologist. 2008;13 Suppl 4:2-9. doi:

10.1634/theoncologist.13-S4-2. PMID: 19001145.

 

59: Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to

ipilimumab in metastatic melanoma: patient cases. Cancer Immun. 2008 Jan 17;8:1.

PMID: 18198818; PMCID: PMC2935787.

 

60: Chen W, Zhang L, Liang B, Saenger Y, Li J, Chess L, Jiang H. Perceiving the

avidity of T cell activation can be translated into peripheral T cell

regulation. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20472-7. doi:

10.1073/pnas.0709878104. Epub 2007 Dec 11. PMID: 18077361; PMCID: PMC2154455.

 

61: Wolchok JD, Saenger YM. Current topics in melanoma. Curr Opin Oncol. 2007

Mar;19(2):116-20. doi: 10.1097/CCO.0b013e32801497c6. PMID: 17272983.

 

62: Saenger Y, Wolchok J. Cytokines in cytotherapy. Cytotherapy.

2006;8(4):313-4. doi: 10.1080/14653240600861226. PMID: 16923605.

red = above full citation